Explore the latest in ovarian cancer, including recent advances in epidemiology, screening, genetic testing, and management of the disease.
This Viewpoint reviews the benefits and risks of risk-reducing mastectomy in otherwise healthy women with BRCA1 and BRCA2 mutations to inform discussions about the proceeding with or foregoing the procedure, and it calls for continued research to understand how to better individualize risk and prevent disease nonsurgically.
This nested case-control study of patients enrolled in Kaiser Permanente Washington quantifies the risk of malignant ovarian cancer based on ultrasonographic characteristics of ovarian masses, including simple cysts, in a large unselected population.
This phase 1 and 2 clinical trial examines progression-free survival in patients with ovarian or breast cancer treated with alisertib in combination with paclitaxel vs paclitaxel alone.
This cohort study uses data from the Nurses’ Health Studies to evaluate associations between use of nonsteroidal anti-inflammatory drugs and risk of epithelial ovarian cancer.
This cross-sectional study investigates the ascertainment of pathogenic and likely pathogenic BRCA1/2 variants among US adults enrolled in the MyCode Community Health Initiative.
In this Medical News article, researchers discuss the outlook for developing effective therapeutic vaccines to treat ovarian cancer.
This study of patients with breast cancer, ovarian cancer, or both compared with controls uses whole-exome sequencing to investigate whether non-BRCA genes are associated with an increased risk of those cancers.
This study uses US community cohort data to assess BRCA1 and BRCA2 testing among medically underserved Medicare beneficiaries with breast cancer, ovarian cancer, or both.
This prospective cohort study examines the association between hormone replacement therapy use after oophorectomy and risk of breast cancer among women with a BRCA1 mutation.
This Viewpoint discusses the implications of the US FDA’s 2018 marketing authorization permitting 23and Me to market BRCA mutation testing to the general public, including concern about overtesting, false assurance, and the ability of accessible testing to improve population health outcomes.
A 56-year-old woman with a history of ovarian cancer and surgical colostomy for small bowel obstruction had a firm, nontender, multilobulated nodule with an ulcerated center adjacent to her stoma, without change despite multiple rounds of antibiotics. What would you do next?
This JAMA Patient Page discusses the US Preventive Services Task Force’s recommendations on screening for ovarian cancer in asymptomatic women.
This systematic review to support the 2018 update of the US Preventive Services Task Force Recommendation Statement on screening for ovarian cancer summarizes published evidence on the benefits and harms of ovarian cancer screening for average-risk, asymptomatic women.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: